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Tumor ecosystems are composed of multiple cell
types that communicate by ligand-receptor interac-
tions. Targeting ligand-receptor interactions (for
instance, with immune checkpoint inhibitors) can
provide significant benefits for patients. However,
our knowledge of which interactions occur in a tumor
and how these interactions affect outcome is
still limited. We present an approach to charac-
terize communication by ligand-receptor interac-
tions across all cell types in a microenvironment
using single-cell RNA sequencing. We apply this
approach to identify and compare the ligand-recep-
tor interactions present in six syngeneic mouse tu-
mormodels. To identify interactions potentially asso-
ciated with outcome, we regress interactions against
phenotypic measurements of tumor growth rate. In
addition, we quantify ligand-receptor interactions
between T cell subsets and their relation to immune
infiltration using a publicly available human mela-
noma dataset. Overall, this approach provides a
tool for studying cell-cell interactions, their variability
across tumors, and their relationship to outcome.INTRODUCTION
The tumor microenvironment is composed of many cell types,
including malignant, stromal, and immune cells. This cellular
complexity of tumors is further increased by the heterogeneity
of each cell type, such as different clones of tumor cells or
the various subsets of immune cells (Jime´nez-Sa´nchez et al.,
2017; McGranahan and Swanton, 2017). These various cell
types all communicate via ligand-receptor interactions, where
the ligand can either be secreted and bind to the receptor in sol-
uble form or bemembrane-bound and require physical proximity
of the two interacting cell types (Ramilowski et al., 2015).
Furthermore, communication between these different cell types
is implicated in mechanisms for tumorigenesis, tumor progres-1458 Cell Reports 25, 1458–1468, November 6, 2018 ª 2018 The Au
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(Hanahan and Weinberg, 2011).
Given the importance of ligand-receptor interactions on pa-
tient outcome, therapeutics that target cell-cell interactions
have become a useful tool in clinical practice. For example, the
immune checkpoint inhibitor ipilimumab targets the CD28 or
CTLA4 interaction, and both pembrolizumab and nivolumab
target the PD1 or PDL1 interaction (Pardoll, 2012). Despite the
clear success of these therapeutics in several tumor types, the
response rates are limited. For instance, only about 20%–25%
of patients respond to immuno-oncology drugs (Dempke et al.,
2017; Schumacher et al., 2015). This limited response rate is
likely because of the complex network of cell-cell interactions
present in a tumor microenvironment, our knowledge of which
is still incomplete (Sarkar et al., 2016). To better stratify patients
for existing therapies as well as to discover interactions that
could be targeted, there is a need to more fully understand the
spectrum of cell-cell interactions occurring in tumor microenvi-
ronments and how these interactions affect outcome.
Single-cell RNA sequencing (scRNA-seq) approaches are
increasingly being used to characterize both the abundance
and functional state of tumor-associated cell types and have
provided unprecedented detail of the heterogeneity of the
cellular composition (Lavin et al., 2017; Tirosh et al., 2016; Zheng
et al., 2017). However, beyond characterizing the cellular
composition of a tumor, it is crucial to understand how the
different cellular components interact with one another to give
rise to emergent tumor behavior. Although examples of using
both bulk and single-cell sequencing data to examine cell-cell
communication exist (Camp et al., 2017; Choi et al., 2015; Costa
et al., 2018; Puram et al., 2017; Skelly et al., 2018; Zhou et al.,
2017), techniques for connecting these features to biological
outcomes of interest and understanding how these interactions
quantitatively relate to specific phenotypic outcomes of interest
are still limited.
Here we developed an approach to characterize cell-cell
communication mediated by ligand-receptor interactions across
all cell types in a microenvironment using scRNA-seq data. After
assigning cell types based on the scRNA-seq data using a deci-
sion tree classifier, our approach quantifies potential ligand-re-
ceptor interactions between all pairs of cell types based on their
gene expression profiles. We demonstrated how this approachthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. T-SNE Visualization of Single-Cell
Sequencing Data and Cell Type Classification
(A) The percentage of cells positive for a variety of
immune cell markers as measured by either scRNA-
seq (x axis) or flow cytometry (y axis) is consistent
across tumor models.
(B and C) t-distributed scholastic neighbor embed-
ding (t-SNE) plots of cells from six syngeneic
tumor models show distinct clusters predominantly
determined by cell type.
(B) Cells are colored by the tumor model from which
the cell originated.
(C) Cells are colored by the cell type label assigned
at the end of the classification procedure.
(D) Percentages of cell types vary across the
different tumormodels. To reflect the actual cell type
abundances, only data from samples not enriched
for CD45 are shown.
See also Figures S1 and S2.can assess similarities and differences in cell-cell communica-
tion between six syngeneic mouse tumor models. We then
extended our approach to quantify ligand-receptor interactions
in human metastatic melanoma samples. Importantly, we exam-
ined the association of individual cell-cell interactions with path-
ophysiological characteristics of the tumor microenvironment.
This work advances conceptual and methodological ap-
proaches for gaining insights from single-cell studies of the tu-
mor microenvironment and has applications for discovering
effective therapeutic targets and biomarkers for stratification of
patient treatment.
RESULTS
scRNA-seq of Syngeneic Mouse Tumor Models
Syngeneic mouse tumor models are frequently used to investi-
gate novel immune-oncology therapeutics (Sanmamed et al.,
2016). However, the different models are still incompletely un-
derstood with respect to ligand-receptor interactions. We
performed scRNA-seq on tumors from six treatment-naive syn-
geneic mouse tumor models (B16-F10 melanoma, EMT6 breast
mammary carcinoma, LL2 Lewis lung carcinoma, CT26 colon
carcinoma, MC-38 colon carcinoma, and Sa1N fibrosarcoma;
two samples per tumor model). Because some models are
poorly infiltrated by immune cells, we additionally enriched forCell RepoCD45-positive cells. Notably, measured
cell frequencies were well correlated
(coefficient of determination [R2] = 0.73,
p = 5.6 3 107) between sorted and un-
sorted populations, with major differences
only noticeable in the B16-F10 model,
which is poorly infiltrated by immune cells
(Figure S1A; Comparison of scRNA-Seq
and Flow Cytometry). In total, we obtained
mRNAmeasurements of more than 10,000
single cells across all models (557 for B16-
F10 cells, 4,479 from CT26 cells, 780 from
EMT6 cells, 1,677 from LL2 cells, 1,310fromMC-38 cells, and 1,670 fromSa1N cells). The average num-
ber of reads per cell was approximately 72,000, and a median of
approximately 2,500 genes was detected per cell (scRNA-seq
Data Processing; Table S1).
To check that our scRNA-seq measurements reflect protein
abundances, we stained the single-cell suspensions from
the same tumors in parallel with antibodies and analyzed ex-
pression of protein marker genes by flow cytometry (Figure 1A;
Table S2). Comparison of the frequencies of single cells positive
for cell surface markers between the scRNA-seq data and
flow cytometry results showed significant correlation between
markers measured using the two approaches (R2 = 0.74,
p = 2.3 3 1028). In addition, we evaluated the similarity of fre-
quencies of five immune cell populations, each defined by two
or three markers, and again found significant correlation be-
tween scRNA-seq and flow cytometry data (R2 = 0.48,
p = 3.4 3 103; Table S2; Figure S1B). Together, these data
indicated that scRNA-seq measurements recapitulate both cell
type abundances and marker expression measured by flow
cytometry.
To aid with visualization of the mouse syngeneic scRNA-seq
data, we used t-distributed stochastic neighbor embedding
(t-SNE), a non-linear dimensionality reduction technique, to
embed the data for all six syngeneic tumor models (Van Der
Maaten and Hinton, 2008; Figure 1B).rts 25, 1458–1468, November 6, 2018 1459
Classification of Cell Types Based on scRNA-SeqData of
Syngeneic Mouse Tumor Models
To begin identifying cell type specific cell-cell communication,
we first identified the cell type of each single cell. Because of lim-
itations in scRNA-seq technology, such as mRNA capture
efficiency, the collected data contained undetected genes (Ko-
lodziejczyk et al., 2015). This phenomenon is collectively called
‘‘zero dropout’’ and makes identification of cell types based on
individual marker genes infeasible for all cells in the dataset.
We therefore refined a previously published supervised classifi-
cation approach for assigning cell types (Schelker et al., 2017).
We first manually defined a list of cell types for which to search
in the dataset and then specified marker genes that define
each cell type (Table S3; Determining Gene Markers for Synge-
neic Tumor Models). To assign individual cells as positive or
negative for each marker gene, we fit Gaussian mixture models
to the expression values of each marker gene and then assigned
each cell in the dataset to one of the mixture components. We
tested Gaussian mixture models containing one through five
components to allow for the possibility of multi-modal gene
expression (Fitting Gaussian Mixture Models to Determine
Marker Expression). However, in all cases except one (Rpl29),
mixture models containing two components best fit the gene
expression profile using the Bayesian information criteria (BIC)
as a metric for model selection (Figure S2C).
After we labeled cells as positive or negative for each marker
gene, we then created a training dataset of high-confidence cells
that matched the specified marker gene profiles for a single cell
type. In this manner, we identified tumor cells from the different
syngeneic models (171 B16-F10 cells, 3,345 CT26 cells, 433
EMT6 cells, 472 LL2 cells, 780 MC-38 cells, and 23 Sa1N cells)
as well as immune and stromal cells (13 B cells, 62 cancer-asso-
ciated fibroblasts [CAFs], 21 endothelial cells, 495 macro-
phages, 23 natural killer [NK] cells, 142 T cells, and 55 dendritic
cells [DCs]). The training data contained roughly two-thirds
(6,035 of 9,232) of all cells and contained cells from all syngeneic
models (220 fromB16-F10 cells, 3,497 fromCT26 cells, 491 from
EMT6 cells, 512 from LL2 cells, 867 from MC-38 cells, and 448
from Sa1N cells). This training dataset was conservative in the
sense that cells affected by zero dropout were excluded. We
then used this ‘‘high-confidence’’ dataset to train a supervised
decision tree classifier that used the full gene expression data
for predicting the cell type of all remaining cells (Figure 1C). To
prevent overfitting, we used only the 500 most variable genes
in the dataset and then performed principal-component analysis
to further reduce the dimensionality of our input data. We kept
only the number of principal components that explained 95%
of the gene expression variance as input features to the classifier
(Training the Decision Tree Classifier). In this way, the classifica-
tion became more robust to zero dropout data and noisy data.
We verified the accuracy of our classifier using 5-fold cross-vali-
dation on the training dataset (Figures S2D and S2E).
Using the trained classifier, we then predicted cell type labels
for all cells present in the dataset. We also computed the prob-
abilities of each assigned label and only retained cells with a
cell type label assigned with more than 95% probability. On
average, about 6% of cells for each model were not assigned
a cell type with more than 95% probability. These unassigned1460 Cell Reports 25, 1458–1468, November 6, 2018cells may be doublets or belong to a cell type not specified by
the original set of markers. In line with observations of human
scRNA-seq data (Puram et al., 2017; Tirosh et al., 2016), the sin-
gle cells from murine syngeneic models clustered by model for
the malignant cells and by cell type for the non-malignant cells
(Figures 1A and 1B), with the exception of macrophages. Given
that macrophages exhibit plasticity dependent on tissue context
(Biswas andMantovani, 2010), it is possible that the clustering of
macrophages by tumor model is due to the distinct microenvi-
ronments of each tumor (Figure S1C). Furthermore, the macro-
phages also appeared to separate according to mouse strain
(Figure S1D).
The frequencies of the identified cell populations in non-CD45-
enriched samples varied among models, illustrating the well-
known variability of immune infiltration to different tumors
(Figures 1D). Within the immune population, macrophages
were the most abundant immune cell type across all models, ac-
counting for 80%–95% of immune cells. All tumors models
showed T cell infiltration, with T cells representing approximately
2%–12% of immune cells depending on the tumor model. The
percentage of NK cells varied from less than 1% of immune cells
in the B16-F10 and Sa1Nmodels to approximately 5% in the LL2
model. B cells were detected in four of the six tumorsmodels and
represented 1%–2% of the total immune cells. Finally, DCs were
the rarest immune cell population and were detected primarily in
the Sa1N tumor model.
Scoring Cell-Cell Interactions Using Known
Ligand-Receptor Interactions
Having defined cell types, we then quantified potential cell-cell
interactions between all cell types present in the tumor microen-
vironment. We used a reference list of approximately 1,800
known, literature-supported interactions containing receptor-
ligand interactions from the chemokine, cytokine, receptor tyro-
sine kinase (RTK), and tumor necrosis factor (TNF) families and
extracellular matrix (ECM)-integrin interactions (Ramilowski
et al., 2015). In addition, we manually added known B7 family
member interactions (Southan et al., 2016) because of their rele-
vance to cancer immunology.
To identify potential cell-cell interactions that are conserved
across the six syngeneic tumormodels, we screened each tumor
model for cases where both members of a given ligand-receptor
interaction are expressed by cell types present within the tumor
microenvironment (Figure 2). We scored interactions by calcu-
lating the product of average receptor expression and average
ligand expression in the respective cell types under examination
(Calculating Ligand-Receptor Interaction Scores). We used the
average expression of each cell type to prevent false negatives
because of zero dropout. After computing scores for each tumor,
we averaged the interaction score across the tumor models to
identify conserved interactions (Figure 2). Given the number of
cell-cell interactions we screened (approximately 1,500 ligand-
receptor pairs after converting to mouse homologs [Human to
Mouse Homolog Conversion] and 64 pairwise combinations of
cell types), we also assessed the statistical significance of
each interaction score using a one-sided Wilcoxon rank-sum
test and performed Benjamini-Hochberg multiple hypothesis
correction. Although we computed interactions for all identified
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Figure 2. Quantification of Cell-Cell Interactions Occurring in the Tumor Microenvironment
Heatmaps show selected interaction scores calculated as the product of the average ligand expression of the first cell type and average receptor expression of
the second cell type. Cell type labels are written as (cell type expressing the ligand) (cell type expressing the receptor). Black dots indicate interactions that are
significantly present across all tumor (one-sided Wilcoxon rank-sum test and Benjamini Hochberg false discovery rate [FDR] < 0.33).
(legend continued on next page)
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cell types, we chose to highlight interactions where either CAFs
or macrophages secrete the ligand because these cell types
were the predominant source of many ligands. In addition, we
examined all interactions involving tumor cells.
Many of the highest-scoring interactions were part of the che-
mokine family. The chemokine interactions detected often
involved the same receptors, including Ccr1, Ccr2, Ccr5, and
their shared ligands, including Ccl2, Ccl4, and Ccl12. Although
chemokine ligands were predominantly expressed by macro-
phages, chemokine and cytokine receptors were expressed
broadly by T cells, B cells, macrophages, and NK cells. In addi-
tion to chemokines, we observed many interactions related to
the extracellular matrix. CAFs secreted numerous ECM compo-
nents, including collagens (e.g., Col1a1 and Col1a2) and fibro-
nectin (Fn1), that bind to adhesion receptors such as integrin
receptors (e.g., Itgb1 and Itga5) and CD44, which were
expressed broadly across all cells. We also observed secretion
of metallopeptidases (MMPs), tissue inhibitors of metalloprotei-
nases (TIMPs), and a disintegrin and metalloproteinases
(ADAMs), which are all involved in modulating the extracellular
environment of tumors.
The observation that many of the highest-scoring interactions
involved common ligands and receptors suggested that inter-
actions scored highly by our metric may be driven predomi-
nantly by expression of one component of a ligand-receptor
interaction. We therefore examined cell type-specific receptor
and ligand expression for all interactions (Figures S3A–S3C).
We first calculated pairwise correlations between ligand
expression, receptor expression, and interaction scores (Fig-
ure S3D) for all ligand-receptor interactions. Neither ligand
expression nor receptor expression was strongly correlated
with the interaction score (median correlations, 0.26 and
0.35, respectively). Furthermore, examining the relationship be-
tween ligand expression, receptor expression, and interaction
score (Figure S3E) showed that, in general, strong interaction
scores occurred only when both the ligand and receptor were
expressed.
Associating Cell-Cell Interaction Scores with
Phenotypes of Interest
We next wanted to address how interaction scores may be used
to gain predictive insights into relevant biological phenotypes of
interest (e.g., outcomes such as tumor growth or anti-tumor im-
mune response). In the absence of a treatment condition, we
used the tumor growth rate for each tumormodel as a phenotype
of interest (Figures 3A and 3B; Table S4). We then computed
Spearman correlations between the interaction scores across
all six tumor models with the tumor growth rate (Figure 3C).
Because we focused on tumor growth rate, we only displayed in-
teractions involving tumor cells, although interactions between
non-tumor cells are also expected to be relevant.
We observed many ECM-related interactions positively corre-
lated with tumor growth. Interactions where both CAFs and(A) Interactions where CAFs secrete the ligand (only interactions with a score gre
(B) Interactions where macrophages secreted the ligand (only interactions with a
(C) Interactions involving tumor cells (only interactions with a score greater than
See also Figure S3.
1462 Cell Reports 25, 1458–1468, November 6, 2018endothelial cells expressed collagens that bind to either Cd93
or integrin receptors on tumor cells were positively correlated
with tumor growth rate. Furthermore, additional adhesion-
related interactions, such as the expression of intercellular adhe-
sion molecules (ICAMs) binding to integrins were also positively
correlated with tumor growth rate. Expression of the Adam12
and Adam15 proteases also correlated with tumor growth,
although these proteases appeared to have opposing effects.
Although interactions between Adam12 and its integrin sub-
strates were negatively correlated with tumor growth rate, inter-
actions involving Adam15 and Integrin beta 3 (Itgb3) were
positively correlated with tumor growth rate.
We also observed numerous chemokine and cytokine inter-
actions correlated with tumor growth rate. The expression of
Ccl11 by tumor cells that interacts with either Ccr5 or Cxcr3
receptors expressed on both macrophages and tumors cells
was positively correlated with tumor growth rate. In addition,
the interactions of interleukin 1 alpha (Il1a) expressed by
CAFs with its cognate receptors IL1r1, IL1r2, and IL1rap ex-
pressed on tumor cells were all negatively correlated with tu-
mor growth rate.
Numerous interactions involving RTKs, which did not show up
among the most strongly occurring interactions (Figure 2), were
correlated with tumor growth rate. The autocrine interaction
involving tumor cells that both secrete epidermal growth factor
(EGF) and express Erbb3 receptors was positively correlated
with tumor growth. In addition, interactions between CAFs
secreting platelet-derived growth factor (PDGF) (Pdgfc and
Pdgfd) and vascular endothelial growth factor (VEGF) (Vegfa
and Vegfc) ligands that bind to both PDGF (Pdgfrb) and VEGF
(Kdr/Vegfrr2) receptors on tumor cells were positively correlated
with tumor growth rate.
In general, we observed that many interactions that correlated
strongly with a specific phenotype contain the same receptor but
different ligands. This observation raised the question whether a
specific ligand or receptor drives the correlation rather than the
interaction itself. To examine this possibility, we calculated
Spearman correlations of the receptor expression alone or
ligand expression alone with tumor growth rate. We observed
that interaction scores with a high correlation with phenotype
generally had either a high receptor correlation or high ligand
correlation (Figure 3D). This result is not unexpected given that
interaction scores are a product of receptor expression and
ligand expression and, therefore, are not independent. However,
there were also numerous cases where the interaction score was
strongly correlated with tumor growth rate, but neither the recep-
tor nor the ligand was strongly correlated (i.e., the region in the
center of the plot with ligand and receptor expression between
0.5 and 0.5). In addition, we observed cases where receptor
expression and ligand expression had opposing strong correla-
tions (top left and bottom right regions of the plot), indicating that
interaction score correlation does not simply reflect ligand and
receptor correlations.ater than 2.5 across any cell type pair are displayed).
score greater than 2.5 across any cell type pair are displayed).
1.5 across any cell type pair are displayed).
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Figure 3. Interaction Scores Correlate with
Relevant Characteristics of the Tumor
Microenvironment
(A) Tumor volume (y axis) of treatment-naive mice
measured over time (x axis) (Table S4). Dashed
lines indicate the mean of a syngeneic tumor
model, and shaded areas represent 1 SEM (n = 8
for Sa1N, 7 for LL2, 10 for CT26, 9 for EMT6, and 9
for MC38). Instances with no shading result from
only one mouse surviving at the measured time
points. Linear curves were fit to the log-normalized
growth curves, and the slope of fit curveswas used
as a metric for tumor growth.
(B) Quantified growth rates for each model. Each
point represents a singlemouse, and the horizontal
black line indicates the median growth rate used
for correlation with interaction scores.
(C) Heatmap showing the Spearman correlation of
interaction scores (shown in Figure 2) with tumor
growth. Interactions marked with black circles
indicate correlations with p < 0.01. Grey boxes
indicate interactions for which the interaction
score was zero across all models and no correla-
tion could be computed.
(D) Distribution of receptor only, ligand only, and
interaction score correlations. Each point repre-
sents an interaction (only autocrine interactions
between tumor cells are displayed). The x axis
represents the correlation of ligand expression
alone with tumor growth rate, whereas the y axis
represents the correlation of the receptor expres-
sion alone with tumor growth rate. Points are
colored according to the strength of correlation of
the interaction scores with tumor growth rate. Gray
points represent interactions that were not de-
tected across all syngeneic tumor models.Quantifying Interactions in Human Metastatic
Melanoma
We next applied our approach for quantifying cell-cell interac-
tions to a published human dataset of metastatic melanoma
(Tirosh et al., 2016).We applied the same classification approach
to identify cell types and quantify cell type percentages using
markers identified by Tirosh et al. (2016) (Analysis of Human
Metastatic Melanoma; Figures S4A and S4B). In addition, we
selected cells predicted to be T cells and again applied our clas-Cell Reporsification procedure to further categorize
cells into CD8+ cells, T helper cells, or
regulatory T cells (Tregs).
Given the complex interactions be-
tween T cells in the tumor microenviron-
ment and their importance in mounting
a successful immunotherapy response,
we investigated interactions involving
Tregs (Figure 4A). We again observed
many interactions involving members
of the chemokine family. As before,
numerous chemokine interactions shared
the same ligands, including CCL3, CCL4,
and CCL5, secreted by B cells, macro-
phages, as well as all T cell subsets. Inaddition, we observed cytokine interactions involving the IL10
and IL15 ligands and the IL10RA and IL2RG receptors, respec-
tively. Because of the known immunosuppressive role of Tregs,
we also examined individual tumors for B7 family interactions
where Tregs expressed the ligand and CD8+ T cells expressed
the receptor (Figure 4B). We observed expression of numerous
inhibitory interactions, including the CD274 (PD-L1)-PDCD1
(PD-1), CTLA4-CD80, and CTLA4-CD86 interactions. However,
although these B7 interactions occurred, on average, acrossts 25, 1458–1468, November 6, 2018 1463
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Figure 4. Assessing Cell-Cell Interactions Occurring in Human Metastatic Melanoma
(A) Cell-cell interactions involving Tregs in human metastatic melanoma averaged across 19 tumor samples. The cell type labels are written as (cell type ex-
pressing the ligand)  (cell type expressing the receptor). Black dots indicate interactions that are significantly present across all tumors (one-sided Wilcoxon
rank-sum test and Benjamini Hochberg FDR < 0.05). Only interactions with a score greater than 0.5 across any cell type pair are displayed.
(B) Examination of tumor-specific interactions in the B7 family between CD8+ T cells and Tregs shows that interactions that occur on average in (A) do not occur in
all individual patients.
(C) Example interactions betweenmacrophages and CD8 cells where the receptor and ligand components of an interaction do not individually correlate with Treg
percentage but the interaction score is strongly correlated with phenotype.
(D) Distribution of Spearman correlation coefficients between Treg percentage and randomized ligand-receptor interactions from (C). Red lines indicate the
Spearman correlation of the actual ligand-receptor pair. The p values indicate the probability that a randomized interaction pair has a stronger correlation than the
actual interaction pair.
See also Figure S4.
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all melanoma samples, examination of individual tumors re-
vealed that these interactions are patient-specific (compare Fig-
ures 4A and 4B).
We again wanted to assess the value of interaction scores
compared with analysis of receptors or ligands alone. In addi-
tion to calculating the correlation of interaction scores with
phenotype, we also computed the correlation of receptor
expression or ligand expression with phenotype. Despite the
general correlation between interaction score correlation and
receptor and/or ligand correlation, we again observed cases
where neither the receptor nor the ligand was strongly corre-
lated with phenotype, but the interaction score was strongly
correlated (Figure 4C).
To understand the probability of observing a ligand-receptor
pair correlate with Treg percentage despite neither the receptor
nor ligand correlating with Treg percentage, we re-computed
correlations using randomized ligand-receptor pairs (Computing
Correlations of Randomized Interaction Scores). We assessed
the significance of interactions identified in Figure 4C by using
randomized interactions with one member of the ligand-recep-
tor interaction being the same and randomizing the other mem-
ber of the interaction (i.e., using the same ligand but calculating
the interaction score with a random receptor and vice versa).
We then compared the correlations of these randomized pairs
with the observed correlation for the actual interaction (Fig-
ure 4D). For both interactions identified in Figure 4C, random
interaction pairs did not correlate as strongly as the real inter-
action. In addition, we calculated the probability that an interac-
tion between a ligand and random receptor would correlate
more strongly than the original correlation of the ligand (Fig-
ure S4E). In general, the stronger the ligand correlation, the
less likely a random ligand-receptor pair is to exhibit a greater
correlation. Furthermore, this result demonstrates that ligand-
receptor pairs are not expected to correlate with phenotype
by chance, even when ligand expression alone is strongly
correlated with phenotype.
To examine how interaction scores relate to phenotypes of
interest in the context of human metastatic melanoma, we
used the percentage of Tregs of the number of T cells in the
tumor as a phenotype. Given that we calculated scores for
19 different tumor samples, in addition to using spearman cor-
relation, we also constructed a predictive model using least ab-
solute shrinkage and selection operator (LASSO) regression.
For the human melanoma dataset, we started with 9,408
measured cell-cell interactions as predictors (of a total possible
of 187,000 = 100 cell type pairs 3 1,870 ligand-receptor inter-
actions). We then trained a regression model using 5-fold
cross-validation and identified a set of 11 interactions capable
of predicting Treg percentage (Figures S4C and S4D). Interac-
tions involving the tumor necrosis factor family receptor
TNFRSF25 expressed on Tregs and its ligand TNFSF15, as
well as interactions involving TNFRSF21 receptors expressed
on macrophages, were predictive of the percentage of Tregs.
In addition, the interaction between B cells producing PSEN1,
a proteolytic enzyme required for NOTCH receptor maturation,
and the NOTCH2 receptor expressed on Tregs (Struhl and
Greenwald, 1999) was also predictive of the percentage of
Tregs.DISCUSSION
In this work, we developed a computational approach for
analyzing scRNA-seq data to screen for ligand-receptor interac-
tions across all cell types present in a tumor microenvironment.
We applied this approach to identify cell-cell interactions com-
mon across six different syngeneic mouse tumor models and
to identify patient-specific interactions in human metastatic mel-
anoma. Furthermore, we demonstrated how these interaction
scores can be used as features in correlative and predictive
models to identify ligand-receptor interactions as biomarkers
or potential therapeutic targets.
Foundational work by Ramilowski et al. (2015) not only cata-
loged known ligand-receptor pairs but also examined 144 cell
types derived from primary tissue for ligand-receptor expres-
sion. The tool provided by Ramilowski et al. (2015), although
providing an excellent draft of ligand-receptor communication,
does not provide a way to examine how interactions might
change in different contexts. When examining malignant tissues,
it is not expected that expression of ligands and receptors in a
tumor will be identical to expression in the primary tissue of
origin. In addition, ourmethodology enables study of interactions
in a data-driven manner when comparing different experimental
perturbations (i.e., treated versus untreated tumors). Beyond the
study by Ramilowski et al. (2015), numerous studies have also
begun to utilize single-cell sequencing data to characterize
cell-cell communication (Camp et al., 2017; Choi et al., 2015;
Costa et al., 2018; Puram et al., 2017; Skelly et al., 2018; Zhou
et al., 2017). The increasing number of these studies examining
cell-cell communication underscores the utility of the approach.
However, a key next step beyond characterizing the interactions
present in a given tissue or tumor microenvironment is to under-
stand how these interactions relate to an outcome of interest
(e.g., tumor growth, response, or resistance to therapy).
In this study, we used correlative and predictive models to
identify cell-cell interactions that may be related to tumor pheno-
types of interest. Recent studies have demonstrated that the
location and abundance of immune cells are predictive of patient
outcome for standard therapies (Ino et al., 2013). For example,
the presence of relevant T cell populations correlates with treat-
ment efficacy for checkpoint inhibitors like anti-PD1, anti-PDL1,
and anti-CTLA4 antibodies (Shang et al., 2015). However, the
limited response rate to current therapeutic approaches under-
scores the fact that cellular abundance alone does not fully pre-
dict patient-specific responses. Explicit consideration of cell-cell
interactions can provide additional insight to improve predicting
response to therapies.
Many of the cell-cell interactions that correlated with tumor
growth rate in the syngeneic tumor models have known associ-
ations with tumor growth rate. For example, numerous interac-
tions involving the binding of tumor cells to ECM components
(e.g., collagens and fibronectins) via integrin receptors were
positively correlated with tumor growth rate. This result supports
the well-established role of the ECM in modulating tumor pro-
gression (Pickup et al., 2014; Venning et al., 2015). Similarly, in-
teractions involving the Ccr5 receptor and its ligands as well the
cell type specificity of the interaction are supported by literature
(Halama et al., 2016). For predicting the percentage of Tregs inCell Reports 25, 1458–1468, November 6, 2018 1465
human metastatic melanoma, the LASSO regression model
selected interactions involving the TNFRSF25 receptor ex-
pressed on Tregs and its ligand TNFRSF15 expressed by T
helper (Th) cells as well as an interaction between PSEN1 ex-
pressed by B cells and the NOTCH2 receptor expressed on
Tregs. Previous studies have shown that decreases in Notch2
expression can reduce the proportion of Tregs, whereas agonist
antibodies targeting the TNFRSF25 receptor can help expand
Treg populations (Bittner et al., 2017; Qin et al., 2017; Schreiber
et al., 2010). Altogether, these results suggest that our approach
of linking cell-cell interactions to phenotypes of interest has the
potential to identify biologically relevant interactions.
Although our results suggest that many interactions correlated
with phenotypes of interest are biologically relevant, it often re-
mains a challenge to identify the causal or mechanistic impor-
tance of individual correlates or predictive features. By using
expression data to examine the activation state of intra-cellular
signaling pathways or transcription factors downstream of impli-
cated receptor-ligand interactions, further insights into biological
mechanisms could be obtained (Garcia-Alonso et al., 2017;
Schubert et al., 2018). Examination of interactions across all pair-
wise cell types also showed that the same ligand-receptor inter-
action can have opposite correlations with a given phenotype
depending on the interacting cell types. These opposing effects
highlight the potentially pleiotropic role of any specific ligand-re-
ceptor interaction and the need to account for the effects of dis-
rupting an interaction across all cell types to fully comprehend
the likely effect of a proposed treatment.
Another distinction separating our work from published single-
cell sequencing studies is the classification approach we use for
determining cell types. A common approach for identifying cell
types is to cluster cells based on gene expression data and
then manually assign a cell type label to each cluster. However,
determining the number of clusters is often a subjective process.
Furthermore, there is an implicit assumption with this approach
that clusters will be based predominantly on cell type. However,
when clustering in a high-dimensional space, clusters may form
on a variety of factors (e.g., cell cycle stage), and trying to assign
a cell type label to each apparent cluster can lead to errors. This
can become especially problematic when trying to identify sub-
types with more subtle or continuous transitions (e.g., CD8+, Th,
or Treg cells or M1 orM2-likemacrophages). Although t-SNE is a
powerful visualization tool for single-cell sequencing data, prox-
imity in t-SNE mappings is often used as evidence of belonging
to the same cell type. Although t-SNE predominantly appears to
form clusters based on cell type, the mapping is not guaranteed
to always group cells by cell type, and the ‘‘accuracy’’ of separa-
tion is not well understood. The classification approach pre-
sented in this work provides a more quantitative and less
subjective approach for cell type classification.
Several factors may lead to the identification of false positives
when using our approach to identify potential cell-cell interac-
tions based on expression of both members of a ligand-receptor
interaction. The level of transcripts does not necessarily corre-
late to protein expression for any gene. Furthermore, because
scRNA-seq does not preserve spatial information, identified in-
teractions in which the receptor and the ligand are membrane-
bound may not occur when the corresponding cell types are1466 Cell Reports 25, 1458–1468, November 6, 2018not spatially co-localized in a tumor. By using antibodies to
detect protein levels, approaches such as multiplexed immuno-
fluorescence imaging or imaging mass cytometry can validate
that membrane-bound interaction components are spatially
co-localized (Bodenmiller, 2016; Lin et al., 2015; Schapiro
et al., 2017). However, these approaches are not suitable for
high-throughput screening of ligand-receptor interactions. In
addition, studies examining cell-cell interaction in the tumor
microenvironment should consider the specificity of those inter-
actions to the tumor microenvironment. When available, the
approach presented in this paper can also be used to compare
the interaction strengths observed in the tumorwith those in con-
trol tissue from the same donor, such as nearby tissue of the
same type or peripheral blood. In this manner, tumor-specific
cell-cell interactions can be identified.
Our methods provide a screening approach to identify
potential ligand-receptor interactions that occur in a tumor
microenvironment. The ability to examine cell type-specific
communication provided by scRNA-seq enables a broad range
of applications. For example, examining samples from different
locations within the tumor can provide insights into the heteroge-
neity of cell-cell interactions within a given tumor. Experiments
examining tumors from distinct metastatic locations could reveal
how various tissue microenvironments influence which cell-cell
interactions occur. Given that many therapeutics target cell-
cell interactions, this approach can be used to both identify
potential targets or to validate that a target of interest is present.
Using this approach in experimental studies that examine
patient-specific responses can identify interactions that are pre-
dictive biomarkers of response to therapy for use in patient
stratification.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal models
In our study we used three different types of immuno-competent inbred mouse strains: BALB/c (Charles River Laboratories, BALB/
cAnNCrl), C57B6/J (Charles River Laboratories, C57BL/6NCrl), and A/J (Charles River Laboratories, A/JCr). All animals enrolled in our
study were 6-8 weeks old female mice that were housed in vivarium under specific pathogen free conditions in cages of up to 5 an-
imals and receiving special rodent diet (Teklad). Studies were approved byMerrimack’s Institutional Animal Care andUseCommittee
(IACUC) under animal protocol MAP#013. IACUC guidelines on the ethical use and care of animals were followed.
Cell lines
For our tumor models, we used six different syngeneic mouse tumor cell lines. The CT26 cancer cell line was obtained from ATCC,
maintained in RPMI-10%FBS at 37C, and implanted into BALB/cmice subcutaneously at 1x106 cells permouse. TheMC-38 cancer
cell line was obtained from NCI/NIH, maintained in RPMI-10% FBS at 37C, and implanted into C57B6/J mice subcutaneously at
2x105 cells per mouse. The EMT6 cancer cell line was obtained from ATCC, maintained in RPMI-10% FBS at 37C, and implanted
into BALB/c mice subcutaneously at 2x105 cells per mouse. The LL2 cancer cell line was obtained from ATCC, maintained in RPMI-
10% FBS at 37C, and implanted into C57B6/J mice subcutaneously at 2x105 cells per mouse. The Sa1N cancer cell line was ob-
tained from ATCC, maintained in Eagle’s Minimum Essential Medium (EMEM, ATCC 30-2003) at 37C, and implanted into A/J mice
subcutaneously at 1 x106 cells per mouse. The B16-F10 cancer cell line as obtained from ATCC, maintained in RPMI-10% FBS at
37C, and implanted into C57B6/J mice subcutaneously at 2x105 cells per mouse.
METHOD DETAILS
scRNA-seq of mouse syngeneic tumor models
We implanted two mice for each syngeneic model resulting in a total of 12 samples. Each mouse tumor was harvested when the tu-
mor size reached 100 – 200mm3. Each sample wasminced and digested with reagents fromMouse Tumor Dissociation Kit (Miltenyi)
according to the manufacturer’s instructions. Cells were resuspended at 2x105 cells/mL in PBS-0.04% BSA. Each sample was pro-
cessed individually and run in technical duplicates. For each sample (except CT26 and MC-38) one replicate was enriched for CD45
positive cells. Live CD45 positive cells were sorted with BD Aria after staining with FITC-CD45 (Biolegend) and 7-AAD. Single cell
suspensions of all samples were resuspended in PBS-0.04% BSA at 5x105 cells/mL and barcoded with a 10x Chromium Controller
(10x Genomics). In total, this procedure resulted in 24 samples. RNA from the barcoded cells for each sample was subsequently
reverse-transcribed and sequencing libraries were constructed with reagents from a Chromium Single Cell 30 v2 reagent kit
(10x Genomics) according to the manufacturer’s instructions. Sequencing was performed with Illumina HiSeq according to the
manufacturer’s instructions (Illumina).
Comparison of scRNA-seq and flow cytometry
Each of the 24 single cell suspensions was stained for with the following antibodies to quantify the frequencies of various live immune
cell populations. Panel one included FITC-CD45, 7-AAD, AF700-CD8, PE-CF594-CD44, BV421-CD127, BV510-CD3, BV570-CD4,
BV605-KLRG1 and BV650-CD25. Panel two included FITC-CD45, PECy7-CD11b, 7-AAD, AF700-CD86, APC-Cy7-Ly6C, PE-
CF594-CD40, BV421-CD11c, BV570-Ly6G and BV650-HLA-DR. Panel three included FITC-CD45, PECy7-CD317, 7-AAD, APC-
CD206, AF700-CD86, APC-Cy7-GR1, PE-CF594-CD40, BV421-F4/80, BV605-NKp46 and BV650-B220. CD317 antibody was
purchased from eBiosciences. CD8, Ly6C and CD40 antibodies were obtained from BD PharMingen. All other antibodies were pur-
chased from Biolegend. Flow cytometry data were obtained on BD Fortessa and analyzed with FlowJo. After gating, the percentage
of marker-positive cells was compared to the percentage of cells with at least one transcript detected in the scRNA-seq data.
QUANTIFICATION AND STATISTICAL ANALYSIS
Single cell RNA sequencing data processing
FASTQ files were processed with the CellRanger software (10x Genomics, Inc., version 2.0). Mouse genome 10-1.2.0 was used as
the reference genome (10x Genomics, Inc.) to generate the matrix files containing cell barcodes and transcript counts. Statistics on
the sequencing results are available in Table S1. The total number of readswas 532,180,635. To distinguish true cells fromdead cells,
debris or background, we used a cut-off of 1,500 on the number of genes detected per barcode, resulting in 10,573 true cells. The
mean number of reads per cell was 72,182, the median detected genes per cell was 2,423 (after cut-off), and the median unique
molecular identifiers (UMIs) per cell was 10,051. After conversion to transcript-per-million (TPM) values, we computed expressione2 Cell Reports 25, 1458–1468.e1–e4, November 6, 2018
levels as Ei,j = log2(TPMi,j+1), where TPMi,j refers to the TPM for gene i in sample j.We then normalized each cell to its average expres-
sion level of 3559 housekeeping genes by adding the average log-normalized housekeeping expression value (equivalent to scaling
first) (Eisenberg and Levanon, 2013).
Determining gene markers for syngeneic tumor models
To assign markers for the malignant cell types, we took advantage of the observation that malignant cells tend to form distinct clus-
ters in t-SNE plots (Tirosh et al., 2016). We first performed density-based clustering (DBSCAN) on the result of our t-SNE mapping
(Figure S2A). We then assumed that cells in clusters predominantly containing cell types from only one tumor model were malignant
cells of that tumor model. For each tumor cluster, we then tested all genes in our dataset as univariate predictors of cluster mem-
bership (i.e., a one-versus-rest classifier) and calculated AUC values as a metric for predictive ability. Finally, we manually selected
top-ranking genes based on biological relevance to the tumor model. For example, in the case of the B16-F10 melanomamodel, top
rankingmarkers included bothMlana, a tumor antigen expressed on the surface of melanoma cells, and Tyrp1, amelanocyte specific
gene related to melanin synthesis.
Fitting Gaussian mixture models to determine marker expression
To identify cells positive for a specified marker gene, we fit Gaussian mixture models (GMMs) to the log-normalized expression
values. For eachmarker gene, we testedmodels containing one through fiveGaussian components. For eachmarker gene and num-
ber of components, we fit models on five randompartitions of the gene expression data.We then computed the Bayesian information
criterion (BIC) of theGMM for eachmodel. To select the number ofmixture components for eachmarker gene, we selected themodel
with the fewest number of components that had an average BIC value within one standard error of the minimum BIC value
(Figure S2C).
Training the decision tree classifier
To create the training dataset used for cell type classification, we used a pre-defined set of 45 marker genes (Schelker et al., 2017).
Each marker gene is labeled as either an AND gene, which should be present in the cell type or a NOT gene, which should be absent
from the cell type. We then created the training dataset by selecting cells that express all AND markers and do not express all NOT
markers. To train the classifier, we used the full gene expression data as an input to predict the assigned training label. We first select
the 500 most variable genes and then perform PCA to further reduce the input dimensionality. We keep the number of principal com-
ponents that explain 95%of the input variance as features for the classifier. Decision trees were fit using theMATLAB fitctree function
using the default parameters, except for theMaxNumSplits parameter that was set to 100. To evaluatemodel accuracy, we used only
cells that have a posterior probability of prediction greater than 95%. We then calculated the overall and cell type specific accuracy
rates using 5-fold cross-validation.
Calculating ligand-receptor interaction scores
To identify potential cell-cell interactions we scored a given ligand-receptor interaction between cell type A and cell type B as the
product of average receptor expression across all cells of cell type A and the average ligand expression across all cells of cell
type B.
Interaction scoreðreceptor; ligand; cell type 1; cell type 2Þ= 1
ncelltype1
X
i˛cell type 1
ei;receptor 3
1
ncelltype2
X
j˛cell type 2
ej;ligand
ei;j = expression of gene j in cell i
nc = number of cells of cell type c
To identify significant interactions, we performed a one-sidedWilcoxon rank-sum test to test the hypothesis than themedian inter-
action score across all tumors is greater than 0. We also used the Benjamini Hochberg method to correct for multiple hypothesis
testing.
Human to mouse homolog conversion
We converted between human and mouse homologous genes using HomoloGene IDs provided in the Mouse Genome Informatics
database (Blake et al., 2017).
Analysis of human metastatic melanoma
Markers for cell type identification were taken from directly from Tirosh et al. (2016). We applied the same pre-processing and clas-
sification approaches as described for the mouse syngeneic studies. To identify T cell subsets, we first predicted T cells from the full
dataset, and then further categorized cells predicted as T cells into either CD8+ positive cells (CD8A+, CD8B+, CD4-), T-helper cells
(CD8-+, CD8B-, CD4+, FOXP3-, CD25-), or Tregs (CD8A-, CD8+, CD4+, FOXP3+, CD25+) using the same classification approach
described above. We then calculated interaction scores and significance using the approach described above.Cell Reports 25, 1458–1468.e1–e4, November 6, 2018 e3
LASSO regression models
Human metastatic interaction scores were normalized across tumors to range [0,1] for use as predictors in LASSO regression
models. LASSO regression models were fit using the MATLAB lasso function and 5-fold cross-validation. After screening a range
of regularization values, we selected the value with mean-squared error (MSE) within one standard error of the minimum MSE.
Computing correlations of randomized interaction scores
Our list of ligand-receptor interactions contained 645 unique ligands and 589 receptors, which resulted in a total of 379,905 possible
random ligand-receptor pairs. With 10 different cell-types identified in the human metastatic melanoma analysis, this resulted in a
total of 37,990,500 cell type specific random interactions. For each possible cell-type specific randomized interaction pair, we calcu-
lated the spearman correlation between Treg percentage with the interaction score of the random pair. To calculate p values, we
divided the number of random interactions pairs with stronger correlation than the true interaction by the total number of random
pairs.
DATA AND SOFTWARE AVAILABILITY
The accesion number for accessing the syngeneicmouse single-cell expression data reported in this paper is GEO: GSE121861. The
accession number for the single-cell sequening data from Tirosh et al. (2016) reported in this paper is GEO: GSE72056. All analysis
code is available on Github at https://github.mit.edu/mkumar/scRNAseq_communication.e4 Cell Reports 25, 1458–1468.e1–e4, November 6, 2018
